Risultati della ricerca - Shanu Modi

Raffina i risultati
  1. 1
    Ganetespib: research and clinical development

    Ganetespib: research and clinical development di Shanu Modi, Komal Jhaveri

    Pubblicazione 2015
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    HER2 breast cancer therapies: a review

    HER2 breast cancer therapies: a review di Shanu Modi, Conleth G. Murphy

    Pubblicazione 2009
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Unlocking the potential of antibody–drug conjugates for cancer therapy

    Unlocking the potential of antibody–drug conjugates for cancer therapy di Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty

    Pubblicazione 2021
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions di Emanuela Ferraro, Joshua Z. Drago, Shanu Modi

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers di Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis

    Pubblicazione 2011
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment di Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone

    Pubblicazione 2011
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Beyond HER2: Targeting the ErbB receptor family in breast cancer

    Beyond HER2: Targeting the ErbB receptor family in breast cancer di Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi

    Pubblicazione 2022
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  8. 8
    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane di Monica Fornier, Shanu Modi, Katherine S. Panageas, Larry Norton, Clifford A. Hudis

    Pubblicazione 2005
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer di Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney

    Pubblicazione 2024
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Chaperome heterogeneity and its implications for cancer study and treatment

    Chaperome heterogeneity and its implications for cancer study and treatment di Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis

    Pubblicazione 2018
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer di Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer di Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer di Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies di Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano

    Pubblicazione 2021
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  15. 15
    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation di T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan

    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan di Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi

    Pubblicazione 2023
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors di Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer di Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies di Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata

    Pubblicazione 2024
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer di Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: